INSIDER
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

Robinhood Chain…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources
SEC FORM 427m ago
HOUSE PTR27m ago
SEC 13F27m ago
ROBINHOOD CHAIN27m ago
Public company

ASTRAZENECA PLC

AZNCIK 0000901832

EDGAR filingsOpen in network
Price$186.43
1 year+14.9%
Disclosed transactions2
Buys / sells0 / 0
Max Insider Score9
Connections with evidence6

AZN · disclosed activity on price

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
9
SM
Sharma ManiSee remarks
AZNASTRAZENECA PLC
Grant or award
A$320
2 sh
Oct 6, 2026Oct 8, 2026

Verified connections

  • In industryevidence
    Pharmaceuticals, devices & health servicesSEC SIC 2834 · Pharmaceutical Preparations · Nov 4, 2026
  • ← Lobbied forevidence
    W STRATEGIES, LLCLDA Q2 2026 second quarter · Medicare/Medicaid · Aug 26, 2026
  • ← Lobbied forevidence
    TIBER CREEK GROUPLDA Q1 2026 first quarter · Medicare/Medicaid, Health issues · Aug 26, 2026
  • ← Lobbied forevidence
    TODD STRATEGY GROUPLDA Q1 2026 first quarter · Medicare/Medicaid, Health issues · Aug 26, 2026
  • ← Lobbied forevidence
traded Oct 6, 2026
+2d
SEC FORM 4

Evidence

9
SM
Sharma ManiSVP, Group Controller
AZNASTRAZENECA PLC
Grant or award
A$327
2 sh
Aug 6, 2026Aug 7, 2026
traded Aug 6, 2026
+1dSEC FORM 4

Evidence

TARPLIN, DOWNS & YOUNG, LLC
LDA Q1 2026 first quarter · Budget/appropriations, Medicare/Medicaid, Health issues · Aug 26, 2026
  • ← Insider ofevidence
    Sharma ManiSVP, Group Controller · Aug 7, 2026

    • Lobbying

    $3.96M reported · de-duplicated
    2026 Q2 $1.68M in-house2026 Q1 $2.28M in-house
    • W STRATEGIES, LLC$80K2026 Q1 · posted Aug 26, 2026 · Medicare/Medicaid
    • TIBER CREEK GROUP$80K2026 Q1 · posted Aug 26, 2026 · Medicare/Medicaid, Health issues
    • TODD STRATEGY GROUP$80K2026 Q2 · posted Aug 26, 2026 · Health issues, Medicare/Medicaid
    • TIBER CREEK GROUP$80K2026 Q2 · posted Aug 26, 2026 · Health issues, FOR, Defense, Medicare/Medicaid
    • In-house report$2.28M2026 Q1 · posted Aug 26, 2026 · Health issues, Medicare/Medicaid, Pharmacy, Taxation, Copyright/patent, TAR, Trade
    • TODD STRATEGY GROUP$80K2026 Q1 · posted Aug 26, 2026 · Medicare/Medicaid, Health issues
    • W STRATEGIES, LLC$80K2026 Q2 · posted Aug 26, 2026 · Medicare/Medicaid
    • In-house report$1.68M2026 Q2 · posted Aug 26, 2026 · Health issues, Medicare/Medicaid, Pharmacy, Copyright/patent, TAR, Trade, Labor, Taxation
    • TARPLIN, DOWNS & YOUNG, LLC$80K2026 Q2 · posted Aug 26, 2026 · Budget/appropriations, Medicare/Medicaid, Health issues
    • TARPLIN, DOWNS & YOUNG, LLC$80K2026 Q1 · posted Aug 26, 2026 · Budget/appropriations, Medicare/Medicaid, Health issues

    Connected PAC contributions

    FEC · direct to members

    No contributions from a PAC connected to this company.